Does Botulinum Toxin Type-A Injection an Effective Way of Relieving Pain in Myofascial Pain Syndrome Patients or Not
Launched by BURSA CITY HOSPITAL · Mar 26, 2025
Trial Information
Current as of April 22, 2025
Completed
Keywords
ClinConnect Summary
Visual Analog Scale (VAS), 4-Point Verbal Rating Scale (VRS), Pain Pressure Threshold (PPT), Short Form-36 (SF-36) and Beck Depression Inventory (BDI) tools were used to evaluate findings of the research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Thirty eight patients (27 female, 11 male) admitted to the PM\&R (physical medicine and rehabilitation) department with at least one TP identified at neck, upper back and lower back muscles were included to the study.
- Exclusion Criterias:
- • Recent any injection to TP within the last 2 months, Diagnosed with fibromyalgia syndrome, Having respiratory or cardiovascular diseases, Allergies, Having psychiatric disorders, History of shoulder or cervical intervention within the last year, Cervical myelopathy, radiculopathy, Failure of cooperation.
Trial Officials
Baki Özdemir, MD
Principal Investigator
LHU Ankara Hospital Department of Rheumatology
About Bursa City Hospital
Bursa City Hospital is a premier healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a robust infrastructure, the hospital fosters collaboration between healthcare professionals and researchers to explore new therapies and treatment modalities. By participating in diverse clinical studies, Bursa City Hospital aims to contribute to the global medical community while ensuring the highest standards of safety and ethical practices in all research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
